Dietary Supplements

As in past years, the 2021 summit will feature updates and insights from top FDA officials, including the Office of Dietary Supplement Programs, and industry experts, with a focus on dietary supplement regulatory compliance.

CHPA welcomes Church & Dwight, Co., Inc., Bridges Consumer Healthcare, and Rhinomed Inc. as its newest manufacturer members of the association.

CHPA issued the following statement regarding the changes in leadership at the FDA Office of Dietary Supplement Programs.

CHPA, along with a wide coalition of organizations, co-signed a joint press release in support of the re-introduction of this bipartisan CBD bill.

For its annual year-in-review series, Chain Drug Review featured CHPA's President & CEO, Scott Melville, who offered industry insights from last year and thoughts on the outlook for 2021.

CHPA issued the following statement following the U.S. Departments of Agriculture and Health and Human Services release of the 2020-2025 Dietary Guidelines for Americans.

CHPA released the following statement in response to FDA’s warning that consumers avoid certain male enhancement and weight loss products sold by major online retailers due to hidden, potentially dangerous drug ingredients.

Today’s column in the Los Angeles Times is aligned with calls from responsible manufacturers in the dietary supplement industry who agree that regulations need to be modernized and strengthened.

Expert insights on the importance of proactive health maintenance, including addressing nutrient deficiencies that increase risk of infection and disease.